TLD1433 Mediated Photodynamic Therapy for Bladder Cancer

The first approved indication for Photodynamic Therapy was for Photofrin-mediated PDT in Bladder Cancer in 1993 in Canada. But the therapy fell out of favor with urologists as patient experience delayed morbidity, which manifests itself in atrophy of the bladder muscle.

The webinar will provide the scientific journey from first contact with TLD1433, a ruthenium coordination complex (C49H38Cl2N8RuS3), through in vitro studies leading to the identification of bladder cancer as a potential target when combined with intravesical installation for drug delivery. This was followed by in vivo orthotopic murine studies to determine effective drug and light dose ranges for subsequent human studies. Monte Carlo light propagation simulations using anatomically realistic bladder shapes guided the development of light dose monitoring devices for the phase IB and phase II clinical trials. The design of the first and the current second clinical trial will be presented.

Subject Matter Level: Intermediate - Assumes basic knowledge of the topic

What You Will Learn:
Photodynamic Therapy, while a light-based therapy, is also a drug-based therapy, and thus pharmacological, biological, medical, and physical aspects need to be considered when developing new treatments, particularly when using a novel photosensitizer. Clinical translation also needs to cover legal requirements.

Who Should Attend:
Students in biophotonics who are interested in Photodynamic Therapy or clinical translation.

About the Presenter: Lothar Lilge from Princess Margaret Cancer Centre, University Health Network

Dr. Lilge obtained his M.Sc. in Experimental Physics from the Johann Wolfgang Goethe University in Frankfurt, Germany, and his Ph.D. in Biophysics from the Westfälische Wilhelms University in Muenster, Germany. His Ph.D. studies included 3 years at the Massachusetts General Hospital in Boston, USA. In 1992, he began his postdoctoral training at McMaster University in Hamilton and subsequently at the Ontario Cancer Institute in Toronto. From 1995 to 2002, he worked at Photonics Research Ontario, a provincially funded Centre of Excellence, serving in various positions, including Staff Scientist and Director of Operations for the Biophotonics User Facility. He is a Senior Scientist at the Princess Margaret Cancer Centre at University Health Network, Toronto, Ontario, and holds a status-only faculty appointment in the Department of Medical Biophysics at the University of Toronto. His research focuses on photodynamic therapy, encompassing topics from photosensitizer evaluation to treatment planning and clinical trial support, in oncology and infection control. A second field pertains to the optical identification of disease prevalence in Breast Cancer.